Source BioScience UK Ltd has completed the acquisition of Cambridge Clinical Laboratories (CCL), establishing a more comprehensive clinical diagnostics portfolio that aims to streamline testing services across the research and clinical spectrum. The transaction, announced on 10 April 2025, will see CCL staff and assets relocated to new clinical laboratory facilities at Source BioScience’s Vision Park site in Cambridge.

Integration of complementary diagnostic services

CCL brings expertise in personalised healthcare diagnostic testing across several medical domains including oncology, virology, men’s health, gastroenterology and fertility. These capabilities will complement Source BioScience’s established services in genomics, multiomics, molecular diagnostics, digital pathology and clinical trial support. The acquisition represents a strategic enhancement of Source BioScience’s service portfolio, creating an integrated laboratory service offering that spans from early research through preclinical development to clinical applications. This comprehensive approach is designed to reduce resource fragmentation and minimise data variability when progressing candidates through the development pipeline.

Source BioScience facility at Vision Park, Cambridge

Enhanced laboratory infrastructure

The relocation to the new clinical facilities at Vision Park provides CCL with expanded laboratory space, which Source BioScience indicates will enable increased capacity for existing services while creating opportunities for development of new testing capabilities.The proximity of genomics and clinical services teams at the same site is expected to facilitate closer collaboration, yielding more comprehensive data interpretation for customers with complex research and diagnostic requirements.

Strategic market positioning

Jay LeCoque, Chairman and CEO of Source BioScience, described the acquisition as completing their service offerings: “CCL has a longstanding reputation for its expertise in personalised clinical diagnostic services, and as such, represented the ideal opportunity to complete our service offerings. By investing in a new clinical lab facility and bringing in the talented team at CCL, we will open up significant new market opportunities in clinical diagnostics and be able to support our customers through all stages of their programs.” The combination appears strategically targeted at organisations requiring continuous support throughout the therapeutic development process, from initial research to clinical application.

Implications for service continuity

Tony Cooke, former CEO and CSO of Cambridge Clinical Laboratories, expressed support for the acquisition, noting that joining forces with Source BioScience would “allow us to bring together the talent and expertise of both companies, ultimately adding more capacity for customers to access these cutting-edge research services, and bring new therapies to patients, faster.” For existing CCL clients, the integration into Source BioScience’s larger operational framework offers access to a broader range of complementary services.

Jay LeCoque, Chairman and CEO of Source BioScience